A Bio-Artificial System is a type of system that integrates biological and artificial components in order to create a hybrid system with the capability of performing complex functions. This type of system is designed to combine elements from both the biological world, such as cells, enzymes, and proteins, and the artificial world, such as computers, electronics, and software. By combining these two worlds, a Bio-Artificial System can be used to create powerful tools and processes for a wide range of applications, from medical treatments to agricultural solutions.

Mallinckrodt Pharmaceuticals is a multibillion dollar specialty pharmaceutical company. Our strong ability to master and manage complexity is the key component in making high-quality products that provide value for patients. To learn more about our culture and how to work here, visit our Careers site .

Our strong ability to master and manage complexity is the key component in making high-quality products that provide value for patients. People throughout the world count on Mallinckrodt products every day to help them lead healthier lives. To learn more about our culture and work here, visit our Careers site .

Mallinckrodt pharmaceuticals is a multibillion dollar specialty pharmaceutical company. Our strong ability to master and manage complexity is the key component in making high-quality products that provide value for patients. People throughout the world count on our products every day to help them lead healthier lives .

Our strong ability to master and manage complexity is the key component in making high-quality products that provide value to patients. People throughout the world count on Mallinckrodt products every day to help them lead healthier lives. To learn more about our culture and work here, visit our Careers site .

Our strong ability to master and manage complexity is the key component in making high-quality products that provide value for patients. People throughout the world count on Mallinckrodt products every day to help them lead healthier lives. To learn more about our culture, visit our Careers site .

Hep-Art Medical Devices B.V. is a spin off company of the Academic Medical Center in Amsterdam. The company has developed a robust bio-artificial liver system, the AMC-BAL. The AMC-BAL has been developed to support acute liver failure (ALF) patients to liver recovery or to the moment of donor-liver availability. The AMC-BAL is an extracorporeal supportive device that treats the plasma of the patients and temporarily replaces liver functions. The core of the system is a bioreactor that is loaded with embedded liver cells (hepatocytes). When based on porcine liver cells, the system appeared safe during a first clinical phase 1 study with ALF patients.

21st century medicine has developed hypothermic preservation and cryopreservation techniques. Biopharmaceutical companies get a larger window in which to test new drug candidates on viable tissue slices that function like fresh. Companies providing products containing living biological systems now have an effective partner to fulfill their inventory and supply chain needs .

Vital Therapies is a biotherapeutic company focused on developing a cell-based therapy targeting the treatment of acute liver failure. Their product candidate, the ELAD System, or ELAD, is a bio-artificial liver therapy that operates outside the body, or extracorporeal, and is designed with the proposed intent to allow the patient’s own liver to regenerate to a healthy state, or to stabilize the patient until liver transplant. ELAD is an allogeneic cellular therapy system incorporating their human liver-derived C3A cells contained in four hollow fiber cartridges that are combined with a single-use customized disposable set and a reusable bedside unit. Data from ELAD clinical studies have shown trends that may indicate the potential to increase survival rates in patients with acute liver failure. ELAD has received orphan designation in the United States and Europe for the treatment of acute liver failure. 

Prior to the initiation of their ongoing Phase III clinical trial program, more than 150 subjects have received ELAD therapy in seven clinical trials and through a compassionate use program, which they believe collectively suggests a promising therapeutic profile. They are currently initiating three Phase III clinical trials in various acute liver failure conditions. In March 2013, they initiated VTI-208, a Phase III randomized, controlled clinical trial in 200 subjects with alcohol-induced liver decompensation. In the fourth quarter of 2013, they intend to initiate two additional Phase III randomized controlled trials, VTI-210, in 120 subjects with acute alcoholic hepatitis, and VTI-212, in 126 subjects with fulminant hepatic failure.

Beta-o2 technologies is developing the ßAir, a bio-artificial pancreas (BAP) intended to cure Type 1 diabetes (TID) according to the international diabetes federation, 425 million adults worldwide have diabetes of whom 8-10% are diagnosed as T1D. In diabetes, this fine balance is disrupted leading to increase in blood glucose while, at the same time, target cells are starving. Beta-O2 has solved the two major challenges of islet transplantation –

Mar Cor® is a leading brand of water purification products and services for the hemodialysis and renal markets. Mar Cor was recently acquired by Evoqua Water Technologies LLC (NYSE: AQUA) evoqua has worked to protect water, the environment, and its employees for more than 100 years .

Search and
explore companies

Bio-Artificial System

For more optimized search results,
use multiple english keywords and apply filters

Search and explore companies

Company size

Location